Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab

Condition:   Advanced Cancer
Interventions:   Drug: FLX475;   Drug: Pembrolizumab
Sponsor:   FLX Bio, Inc.
Recruiting

https://ift.tt/2xppUoD